

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Aisling Capital II LP</u> (Last) (First) (Middle) 888 7TH AVENUE 30TH FLOOR (Street) NEW YORK NY 10106 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Esperion Therapeutics, Inc. [ESPR]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2013	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				
Common Stock	07/01/2013		C		1,816,475	A	(1)	1,816,475	I	By Aisling Capital II, L.P. ⁽²⁾	
Common Stock	07/01/2013		P		238,119	A	\$14	2,054,594	I	By Aisling Capital II, L.P. ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	07/01/2013		C			1,816,475	(1)	(1)	Common Stock	1,816,475	\$0	0	I	By Aisling Capital II, L.P. ⁽²⁾
Warrant to Purchase Preferred Stock	\$1 ⁽⁴⁾	07/01/2013		J			497,666 ⁽⁴⁾	(3)	02/12/2018	Series A Preferred Stock	497,666	\$0	0	I	By Aisling Capital II, L.P. ⁽²⁾
Warrant to Purchase Common Stock	\$6.99 ⁽⁴⁾	07/01/2013		J			71,237 ⁽⁴⁾	(3)	02/12/2018	Common Stock	71,237	\$0	71,237	I	By Aisling Capital II, L.P. ⁽²⁾

1. Name and Address of Reporting Person*
Aisling Capital II LP
 (Last) (First) (Middle)
 888 7TH AVENUE
 30TH FLOOR
 (Street)
 NEW YORK NY 10106
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
 AISLING CAPITAL PARTNERS, LP
 (Last) (First) (Middle)
 888 7TH AVENUE,
 30TH FLOOR
 (Street)
 NEW YORK NY 10106

